PE66696A1 - Quinazolinona bisustituida en 2,8 - Google Patents

Quinazolinona bisustituida en 2,8

Info

Publication number
PE66696A1
PE66696A1 PE1996000044A PE00004496A PE66696A1 PE 66696 A1 PE66696 A1 PE 66696A1 PE 1996000044 A PE1996000044 A PE 1996000044A PE 00004496 A PE00004496 A PE 00004496A PE 66696 A1 PE66696 A1 PE 66696A1
Authority
PE
Peru
Prior art keywords
formula
compound
already
linear
branched
Prior art date
Application number
PE1996000044A
Other languages
English (en)
Inventor
Erwin Bischoff
Helmuth Schutz
Elisabeth Perzborn
Wolfgang Hartwig
Fred Robert Heiker
Ulrich Niewohner
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE66696A1 publication Critical patent/PE66696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/92—Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE AL COMPUESTO DE FORMULA I DONDE: A ES OXIRANILO, OPCIONALMENTE SUSTITUIDO POR ALQUILO LINEAL O RAMIFICADO CON HASTA 8 ATOMOS DE CARBONO; D ES H o UN GRUPO DE FORMULA -SO2-NR8R9, DONDE R8 Y R9 SON IGUALES O DISTINTOS Y SIGNIGNIFICAN H, FENILO O ALQUILO LINEAL O RAMIFICADO CON HASTA SEIS ATOMOS DE CARBONO, QUE DADO EL CASO ESTA SUSTITUIDO POR HIDROXILO, O JUNTO CON EL ATOMO DE NITROGENO, FORMAN UN HETEROCICLO SATURADO DE 5 A 6 ESLABONES CON HASTA OTROS DOS HETEROATOMOS DEL GRUPO S, N Y/U O, QUE OPCIONALMENTE ESTA SUSTITUIDO SOBRE UNA FUNCION N LIBRE; E REPRESENTA ALQUILO LINEAL O RAMIFICADO CON HASTA 8 ATOMOS DE CARBONO; TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION CARACTERIZADO POR LA CICLACION DEL COMPUESTO DE FORMULA (II), EN LA CUAL D Y E YA SE DEFINIERON; T ES ALQUILO C1-C4; R10 ES HALOGENO; CON FORMAMIDA, FORMANDO EL COMPUESTO DE FORMULA (III) DONDE D, E Y R10 YA SE DEFINIERON Y LUEGO TRANSFORMACION CON EL COMPUESTO DE FORMULA (IV): R1-CH=CH-R2 EN LA CUAL R1 Y R2 YA SE DEFINIERON, EN DISOLVENTES INERTES, EN PRESENCIA DE UNA BASE Y EN EL SISTEMA TRI-o-TOLIL-FOSFINA/ACETATO DE PALADIO (II), DANDO EL COMPUESTO DE FORMULA (Ia) DONDE: D, E, R1 Y R2 YA SE DEFINIERON, Y DADO EL CASO, SE HIDROGENA EL DOBLE ENLACE. ES USADO EN EL TRATAMIENTO DE LA INFLAMACION, ENFERMEDAD TROMBOEMBOLICA Y DE LA CIRCULACION
PE1996000044A 1995-01-19 1996-01-19 Quinazolinona bisustituida en 2,8 PE66696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501481A DE19501481A1 (de) 1995-01-19 1995-01-19 2,8-Disubstituierte Chinazolinone

Publications (1)

Publication Number Publication Date
PE66696A1 true PE66696A1 (es) 1997-03-09

Family

ID=7751829

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000044A PE66696A1 (es) 1995-01-19 1996-01-19 Quinazolinona bisustituida en 2,8

Country Status (32)

Country Link
US (1) US5721238A (es)
EP (1) EP0722937A1 (es)
JP (1) JPH08253457A (es)
KR (1) KR960029325A (es)
CN (1) CN1134417A (es)
AR (1) AR006738A1 (es)
AU (1) AU704102B2 (es)
BG (1) BG100293A (es)
BR (1) BR9600148A (es)
CA (1) CA2167345A1 (es)
CO (1) CO4700522A1 (es)
CZ (1) CZ16796A3 (es)
DE (1) DE19501481A1 (es)
EE (1) EE9600019A (es)
FI (1) FI960227A (es)
HR (1) HRP960004A2 (es)
HU (1) HUP9600114A3 (es)
IL (1) IL116770A (es)
IN (1) IN184956B (es)
MA (1) MA23780A1 (es)
NO (1) NO307513B1 (es)
NZ (1) NZ280831A (es)
PE (1) PE66696A1 (es)
PL (1) PL312352A1 (es)
RO (1) RO117451B1 (es)
RU (1) RU2158733C2 (es)
SG (1) SG34377A1 (es)
SK (1) SK7796A3 (es)
SV (1) SV1996000005A (es)
TR (1) TR199600029A2 (es)
YU (1) YU1496A (es)
ZA (1) ZA96397B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132757A (en) 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132753A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6194433B1 (en) * 1998-10-05 2001-02-27 Neal R. Cutler Sexual dysfunction in females
US6110489A (en) * 1998-05-01 2000-08-29 Cutler; Neal R. Use of quinolines and quinolones to treat male erectile dysfunction
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6303135B1 (en) 1999-07-08 2001-10-16 Neal R. Cutler Use of quinolines and quinolones to treat male erectile dysfunction
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
CA2420461C (en) * 2000-09-06 2008-08-12 Tanabe Seiyaku Co., Ltd. Preparations for oral administration
US6562838B2 (en) 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
DE60236850D1 (de) 2001-02-15 2010-08-12 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
ATE377009T1 (de) * 2001-11-30 2007-11-15 Osi Pharm Inc Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
DE60318089T2 (de) 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. Protein-tyrosine-kinase-inhibitoren
CA2506897A1 (en) * 2002-12-27 2004-07-15 Tibotec Bvba Fluorogenic enzyme substrates and methods of preparation
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
CN101547922B (zh) * 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011302006A1 (en) 2010-09-15 2013-03-07 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2017503833A (ja) * 2014-01-23 2017-02-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド イカリイン誘導体
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
CN110590769B (zh) * 2019-06-13 2021-09-24 中山大学 一对喹唑啉酮生物碱对映体及其制备方法和应用
WO2024026424A1 (en) * 2022-07-27 2024-02-01 Black Diamond Therapeutics, Inc. Quinazolinone derivatives as and related uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof

Also Published As

Publication number Publication date
IL116770A (en) 2000-08-31
SK7796A3 (en) 1996-08-07
HRP960004A2 (en) 1998-02-28
DE19501481A1 (de) 1996-07-25
HUP9600114A2 (en) 1996-12-30
BR9600148A (pt) 1998-01-06
RU2158733C2 (ru) 2000-11-10
US5721238A (en) 1998-02-24
ZA96397B (en) 1996-08-28
SG34377A1 (en) 1996-12-06
CZ16796A3 (en) 1996-08-14
AR006738A1 (es) 1999-09-29
AU704102B2 (en) 1999-04-15
SV1996000005A (es) 1997-03-11
NO307513B1 (no) 2000-04-17
EP0722937A1 (de) 1996-07-24
MA23780A1 (fr) 1996-10-01
CN1134417A (zh) 1996-10-30
HUP9600114A3 (en) 2000-03-28
EE9600019A (et) 1996-08-15
HU9600114D0 (en) 1996-03-28
RO117451B1 (ro) 2002-03-29
IL116770A0 (en) 1996-05-14
YU1496A (sh) 1998-09-18
NO960222L (no) 1996-07-22
AU4098096A (en) 1996-07-25
FI960227A0 (fi) 1996-01-17
CO4700522A1 (es) 1998-12-29
PL312352A1 (en) 1996-07-22
TR199600029A2 (tr) 1996-08-21
NZ280831A (en) 1996-10-28
CA2167345A1 (en) 1996-07-20
NO960222D0 (no) 1996-01-18
BG100293A (en) 1996-07-31
KR960029325A (ko) 1996-08-17
FI960227A (fi) 1996-07-20
JPH08253457A (ja) 1996-10-01
IN184956B (es) 2000-10-07

Similar Documents

Publication Publication Date Title
PE66696A1 (es) Quinazolinona bisustituida en 2,8
AR025976A1 (es) Inhibidores de fab i.
ES2148120T3 (es) Metodo para la preparacion de citalopram.
ES2091299T3 (es) Compuestos azaesteroides para el tratamiento de la hipertrofia prostatica, su preparacion y uso.
ES2112332T3 (es) Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
HUP9700997A1 (hu) Benzimidazolszármazékok és e vegyületeket tartalmazó, antihisztamin hatású gyógyászati készítmények
ATE82668T1 (de) Benzothiadiazole und ihre verwendung in verfahren und mitteln gegen pflanzenkrankheiten.
PA8444301A1 (es) Compuestos de quinolina y de quinazolina utiles en terapia
AR003433A1 (es) Agente ectoparasiticida, procedimiento para la produccion de dicho agente uso de un compuesto contra insectos parasitos y garrapatas monofagas y para laproduccion de dicho agente.
ES2036551T3 (es) Compuestos heterociclicos.
MX9304698A (es) Heterociclos que contienen nitrogeno substituido.
CO5540391A2 (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibi dores de la fosfodiesterasa
ES2059491T3 (es) Derivados de indol con anillos condensados.
FI875229A (fi) Menetelmä uusien farmakologisesti aktiivisten katekolijohdoksien valmistamiseksi
ES2182114T3 (es) Derivados azabiciclicos de la carbamoiloxi-multilina para empleo antibacteriano.
MX9204914A (es) Nuevos derivados de isatinoxima, metodo para su preparacion y composicion farmaceutica que los comprende.
ES2075004T3 (es) Derivados de pirimidina, procedimientos para su produccion y composiciones herbicidas que los contienen.
AR248011A1 (es) Procedimiento para la fabricacion de un derivado de diamidin-difenil-alquileno.
ES2096396T3 (es) Procedimiento para la obtencion de polimeros, formados por alqu-1-enos con 2 a 10 atomos de carbono con empleo de complejos de metaloceno racemicos como catalizadores.
ES2102043T3 (es) Derivados de 22-en-25-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que los contienen, asi como su utilizacion en calidad de medicamentos.
AR248067A1 (es) Composiciones repelentes de los insectos y los acaros, procedimiento para su obtencion y derivados utiles en dichas composiciones excluyendo su uso en o sobre seres humanos o animales superiores.
FR2436779A1 (fr) Derives de pyrrolidine-2 methanol utilisables comme medicaments
SE9003973D0 (sv) Glycerol, ett framstaellningsfoerfarande foer desamma samt terapeutiska kompositioner innehaallande dem
DK0937043T3 (da) Substituerede tetrahydropyridin-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse derivater
NO175633C (no) Forbindelse, preparat og anvendelse

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed